Faculty profile

Alice Dragomir

ResearcherUniversité de Montréal

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses may be missing. Find their university profile.

Alice Dragomir

Researcher

Health Sciences

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
16 publications in the last five years, latest in 2026.
Senior (last) author on 7 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Drugs Utilisation Economic Evaluation Effectiveness And Toxicity Of Treatments Prostate Cancer Real-Word Evidence

Latest papers

Editorial: Addressing gender inequality in healthcare leadership: a path to enhanced patient outcomes.
Frontiers in public health · 2026
Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis
Journal of Clinical Oncology · 2025
Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study
Clinical Genitourinary Cancer · 2025 · senior author

All 62 publications

Latest funding

Valoriser la donnée de vie réelle pour soutenir l'usage optimal du médicament
CIHR · 2025 · Co-investigator
$742,050
Create timely real-world evidence and economic evaluations to improve decisions for patients with prostate cancer
CIHR · 2024 · Nominated PI
$638,776
New Drug and Technology Assessment in Bladder Cancer: Creation of a Novel Canadian Policy Model for Bladder Cancer
CIHR · 2020 · Co-investigator
$680,085

All 3 grants and awards

62 publications.

Editorial: Addressing gender inequality in healthcare leadership: a path to enhanced patient outcomes.

Özbilgin MF, Yacoubian A, Mukherji D, Dragomir A, El Hajj A

Frontiers in public health2026

DOI: 10.3389/fpubh.2026.1834414 PMID: 42058082

Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis

Marcq G, Kool R, Dragomir A, Kulkarni GS, Breau RH, Kim M, Busca I, Abdi H, Dawidek M, Uy M

Journal of Clinical Oncology202514 citations

DOI: 10.1200/jco.23.02718

Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study

Bou-Nehme Sawaya G, Tanguay S, Wood LA, Kollmannsberger C, Basappa NS, Bansal R, Soulières D, Finelli A, Heng DYC, Castonguay V

Clinical Genitourinary Cancer20252 citationsSenior author

DOI: 10.1016/j.clgc.2025.102342

Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis

Kool R, Dragomir A, Kulkarni GS, Marcq G, Breau RH, Kim M, Busca I, Abdi H, Dawidek M, Uy M

European Urology Oncology202430 citations

DOI: 10.1016/j.euo.2024.01.014

Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

Sawaya GB-N, Dragomir A, Wood LA, Kollmannsberger C, Basappa NS, Kapoor A, Soulières D, Finelli A, Heng DYC, Castonguay V

European Urology Oncology202412 citations

DOI: 10.1016/j.euo.2023.11.016

Cost-Effectiveness of PARP Inhibitors for Patients with BRCA1/2-Positive Metastatic Castration-Resistant Prostate Cancer-The Canadian Perspective.

Yanev I, Aprikian AG, Raizenne BL, Dragomir A

Cancers2024Senior author

DOI: 10.3390/cancers17010040 PMID: 39796671

Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study.

Bárcena PGQ, Aprikian AG, Dragomir A

Cancer medicine2024Senior author

DOI: 10.1002/cam4.6922 PMID: 38351647

Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Québec, Canada.

Wissing MD, O'Flaherty A, Dragomir A, Tanguay S, Kassouf W, Aprikian AG

BMC urology2023

DOI: 10.1186/s12894-023-01287-6 PMID: 37452329

A cost-effectiveness analysis of bladder management strategies in neurogenic lower urinary tract dysfunction after spinal cord injury: A publicly funded health care perspective.

Shamout S, Nazha S, Dragomir A, Baverstock R, Corcos J, Campeau L

Spinal cord2023

DOI: 10.1038/s41393-023-00883-5 PMID: 36894764

Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.

Dragomir A, Touma N, Hu J, Perreault S, Aprikian AG

Journal of the National Comprehensive Cancer Network : JNCCN2023First author

DOI: 10.6004/jnccn.2022.7083 PMID: 36791755

Something wrong or missing on this profile? Suggest a correction

Alice Dragomir

Research

Latest papers

Latest funding

Editorial: Addressing gender inequality in healthcare leadership: a path to enhanced patient outcomes.

Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis

Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study

Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis

Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

Cost-Effectiveness of PARP Inhibitors for Patients with BRCA1/2-Positive Metastatic Castration-Resistant Prostate Cancer-The Canadian Perspective.

Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study.

Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Qu&#xe9;bec, Canada.

A cost-effectiveness analysis of bladder management strategies in neurogenic lower urinary tract dysfunction after spinal cord injury: A publicly funded health care perspective.

Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk.

Valoriser la donnée de vie réelle pour soutenir l'usage optimal du médicament

Create timely real-world evidence and economic evaluations to improve decisions for patients with prostate cancer

New Drug and Technology Assessment in Bladder Cancer: Creation of a Novel Canadian Policy Model for Bladder Cancer

Frequent collaborators

Wassim Kassouf

Lucie Blais

Yola Moride

Yola Moride

Antonio Finelli

Christina Canil

Ramy Saleh

Bobby Shayegan

Jean-Claude Tardif

Eric Winquist

Simon De Denus

Robert Siemens

Jean-Claude Tardif

Aly-Khan Lalani

Andrew Loblaw

Gerard Morton

Nicholas Power

Nicole Mittmann

Rahul Bansal

James Brophy

Ruth Sapir-Pichhadze

Annie Rochette

Anaïs Lacasse

Stanley Liu

Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Québec, Canada.